Patents Assigned to Drug Innovation & Design, Inc.
-
Publication number: 20030138432Abstract: The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.Type: ApplicationFiled: December 15, 2000Publication date: July 24, 2003Applicant: Drug Innovation & Design, Inc.Inventor: Arnold Glazier
-
Publication number: 20010012893Abstract: Disclosed are novel prodrugs represented by the following structural formula: 1Type: ApplicationFiled: December 6, 2000Publication date: August 9, 2001Applicant: Drug Innovation & Design, Inc.Inventors: Arnold Glazier, Milka Yanachkova, Ivan Yanachkov
-
Patent number: 6214811Abstract: Disclosed are novel prodrugs represented by the following structural formula; Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.Type: GrantFiled: February 28, 2000Date of Patent: April 10, 2001Assignee: Drug Innovation & Design, Inc.Inventors: Arnold Glazier, Milka Yanachkova, Ivan Yanachkov
-
Patent number: 6180790Abstract: Disclosed are novel prodrugs represented by the following structural formula: Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.Type: GrantFiled: December 10, 1999Date of Patent: January 30, 2001Assignee: Drug Innovation and Design, Inc.Inventors: Arnold Glazier, Milka Yanachkova, Ivan Yanachkov
-
Patent number: 6140310Abstract: The composition and methods of synthesis of phosphorus prodrugs are described. These methods can be used to convert negatively charged phosphorus bearing drugs into neutrally charged; lipid soluble prodrugs which are able to passively diffuse into cells and into tissues in vivo. Prodrugs for a variety of antiviral and anti-leukemic agents are described.Type: GrantFiled: May 6, 1998Date of Patent: October 31, 2000Assignee: Drug Innovation & Design, Inc.Inventor: Arnold Glazier
-
Patent number: 6031096Abstract: Disclosed are novel prodrugs represented by the following structural formula: ##STR1## Z is oxygen or sulfur; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a substituted benzyl group with one or more protected hydroxy or protected amine groups in the ortho or para positions, relative to the phosphate ester, which can be converted in vivo to a hydroxy or amino group. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.Type: GrantFiled: May 15, 1998Date of Patent: February 29, 2000Assignee: Drug Innovation & Design, Inc.Inventors: Arnold Glazier, Milka Yanachkova, Ivan Yanachkov
-
Patent number: 5789608Abstract: The composition and methods of synthesis of phosphorus prodrugs are described. These methods can be used to convert negatively charged phosphorous bearing drugs into neutrally charged; lipid soluble prodrugs which are able to passively diffuse into cells and into tissues in vivo. Prodrugs for a variety of antiviral and anti-leukemic agents are described.Type: GrantFiled: December 11, 1996Date of Patent: August 4, 1998Assignee: Drug Innovation and Design, Inc.Inventor: Arnold Glazier
-
Patent number: 5789589Abstract: Disclosed are novel prodrugs represented by the following structural formulas: ##STR1## Z is oxygen or sulfur; n is 1 or 2; Y is, together with a hydroxy group, acyclovir or an analog of acyclovir; A is a group which can be metabolized in vivo to a give a modified A such that the phosphoester bond (modified A)--O undergoes cleavage in vivo. Also disclosed is a method of treating a viral infection in an individual or animal. The method comprises administering to the individual or animal a therapeutically effective amount of a prodrug represented by structural formula shown above.Type: GrantFiled: April 22, 1996Date of Patent: August 4, 1998Assignee: Drug Innovation & Design, Inc.Inventor: Arnold Glazier
-
Patent number: 5659061Abstract: The composition, synthesis, and applications of tumor associated protease activated prodrugs of phosphoramide mustard, isophosphoramide mustard and analogs with detoxification functionalities are described. These drugs release a cytotoxic phosphoramide mustard analog following activation by tumor associated proteases and esterases. The general structure for these drugs is: ##STR1## Wherein R1 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; wherein X is a good leaving group such as a halogen; R2 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; or an amino group (NH.sub.2) which may optionally be substituted. Wherein A is a benzyloxy derivative with one or more acyloxy or acylamino groups in para or ortho portions relative to the phosphoester; and wherein the acyloxy or acylamino groups are not (substituted or unsubstituted) p-guanidino-benzoyloxy groups or p-guanidino-benzoylamino groups.Type: GrantFiled: April 20, 1995Date of Patent: August 19, 1997Assignee: Drug Innovation & Design, Inc.Inventor: Arnold Glazier
-
Patent number: 5627165Abstract: The composition and methods of synthesis of phosphorus prodrugs are described. These methods can be used to convert negatively charged phosphorous bearing drugs into neutrally charged; lipid soluble prodrugs which are able to passively diffuse into cells and into tissues in vivo. Prodrugs for a variety of antiviral and anti-leukemic agents are described.Type: GrantFiled: September 23, 1994Date of Patent: May 6, 1997Assignee: Drug Innovation & Design, Inc.Inventor: Arnold Glazier